IN2014MN01962A - - Google Patents
Info
- Publication number
- IN2014MN01962A IN2014MN01962A IN1962MUN2014A IN2014MN01962A IN 2014MN01962 A IN2014MN01962 A IN 2014MN01962A IN 1962MUN2014 A IN1962MUN2014 A IN 1962MUN2014A IN 2014MN01962 A IN2014MN01962 A IN 2014MN01962A
- Authority
- IN
- India
- Prior art keywords
- cabazitaxel
- crystalline form
- preparation
- novel
- novel crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210259595.3A CN102746258B (zh) | 2012-07-25 | 2012-07-25 | 卡巴他赛的结晶形式及其制备方法 |
| PCT/CN2013/079575 WO2014015760A1 (zh) | 2012-07-25 | 2013-07-18 | 卡巴他赛的结晶形式及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01962A true IN2014MN01962A (ru) | 2015-07-10 |
Family
ID=47026807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1962MUN2014 IN2014MN01962A (ru) | 2012-07-25 | 2013-07-18 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9353076B2 (ru) |
| EP (2) | EP3067348A1 (ru) |
| JP (1) | JP6329135B2 (ru) |
| CN (1) | CN102746258B (ru) |
| AU (2) | AU2013295924B2 (ru) |
| CA (2) | CA2870569A1 (ru) |
| IN (1) | IN2014MN01962A (ru) |
| WO (1) | WO2014015760A1 (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2688877B1 (en) | 2011-04-12 | 2017-03-08 | Teva Pharmaceuticals International GmbH | Solid state forms of cabazitaxel and processes for preparation thereof |
| EP2822932A2 (en) | 2012-03-08 | 2015-01-14 | IVAX International GmbH | Solid state forms of cabazitaxel and processes for preparation thereof |
| CN102746258B (zh) * | 2012-07-25 | 2015-02-04 | 重庆泰濠制药有限公司 | 卡巴他赛的结晶形式及其制备方法 |
| CN103804323A (zh) * | 2012-11-14 | 2014-05-21 | 上海希迈医药科技有限公司 | 一种卡巴他赛溶剂化物及其制备方法和应用 |
| CN103819428B (zh) * | 2012-11-19 | 2016-01-13 | 齐鲁制药有限公司 | 7β,10β-二甲氧基多西紫杉醇的溶剂化物的晶型及其制备方法 |
| CN103058960B (zh) * | 2012-12-12 | 2014-12-10 | 江苏奥赛康药业股份有限公司 | 卡巴他赛多晶型形式及其制备方法 |
| KR101429543B1 (ko) | 2012-12-13 | 2014-08-14 | 주식회사 삼양바이오팜 | 카바지탁셀의 신규 결정형 및 그 제조방법 |
| CN103044364B (zh) * | 2013-01-07 | 2016-01-20 | 重庆泰濠制药有限公司 | 一种卡巴他赛无定形晶及其制备方法 |
| WO2014128728A2 (en) * | 2013-02-25 | 2014-08-28 | Laurus Labs Private Limited | Solid forms of cabazitaxel and processes for preparation thereof |
| CN103450119B (zh) * | 2013-09-24 | 2015-06-17 | 天津炜捷制药有限公司 | 一种卡巴他赛晶型w及其制备方法 |
| EP2865674A1 (en) * | 2013-10-23 | 2015-04-29 | INDENA S.p.A. | Crystalline solvate forms of Cabazitaxel |
| CN105461665A (zh) * | 2014-08-21 | 2016-04-06 | 中国医学科学院药物研究所 | 卡巴他赛晶n6型物质及制备方法和其组合物与用途 |
| CN105461664A (zh) * | 2014-08-21 | 2016-04-06 | 中国医学科学院药物研究所 | 卡巴他赛晶n5型物质及制备方法和其组合物与用途 |
| CA3010514A1 (en) | 2016-01-15 | 2017-07-20 | Zhuhai Beihai Biotech Co., Ltd. | Compositions and formulations including cabazitaxel and human serum albumin |
| WO2018047074A1 (en) * | 2016-09-07 | 2018-03-15 | Cadila Healthcare Limited | Sterile injectable compositions comprising drug micelles |
| US11413265B2 (en) | 2018-04-20 | 2022-08-16 | Zhuhai Beihai Biotech Co., Ltd. | Formulations and compositions of Cabazitaxel |
| CN113429369B (zh) * | 2021-07-23 | 2022-12-02 | 无锡紫杉药业有限公司 | 一种高效的卡巴他赛纯化方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20022332A3 (cs) * | 2000-01-07 | 2003-01-15 | Transform Pharmaceuticals, Inc. | Sestava vzorků |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| FR2926551A1 (fr) | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
| CN101525321B (zh) * | 2008-03-06 | 2012-03-07 | 上海希迪制药有限公司 | 多烯紫杉醇倍半水结晶体及其制备方法 |
| PL388144A1 (pl) | 2009-05-29 | 2010-12-06 | Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością | Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie |
| CN102060815B (zh) * | 2010-12-24 | 2012-09-26 | 重庆泰濠制药有限公司 | 一种紫杉烷类化合物的制备方法 |
| EP2688877B1 (en) * | 2011-04-12 | 2017-03-08 | Teva Pharmaceuticals International GmbH | Solid state forms of cabazitaxel and processes for preparation thereof |
| TWI526437B (zh) * | 2011-09-09 | 2016-03-21 | 台灣神隆股份有限公司 | 卡巴他賽之結晶型 |
| WO2013049442A1 (en) * | 2011-09-30 | 2013-04-04 | Life Technologies Corporation | Method and systems for image analysis identification |
| CN102336726B (zh) * | 2011-09-30 | 2014-11-26 | 重庆泰濠制药有限公司 | 一种卡巴他赛的制备方法 |
| CN102503913B (zh) * | 2011-10-20 | 2014-03-26 | 江苏红豆杉生物科技股份有限公司 | 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法 |
| DE112012004569T5 (de) * | 2011-11-01 | 2014-08-14 | Fresenius Kabi Oncology Ltd. | Amorphe Form von Cabazitaxel und Verfahren zum Herstellen davon |
| ES2716799T3 (es) | 2011-11-28 | 2019-06-17 | Fresenius Kabi Oncology Ltd | Forma cristalina de cabazitaxel y proceso para la preparación de la misma |
| JP6025861B2 (ja) * | 2011-12-13 | 2016-11-16 | アベンティス・ファーマ・ソシエテ・アノニム | カバジタキセルの結晶形およびこれを調製するための方法 |
| EP2822932A2 (en) * | 2012-03-08 | 2015-01-14 | IVAX International GmbH | Solid state forms of cabazitaxel and processes for preparation thereof |
| CN102746258B (zh) | 2012-07-25 | 2015-02-04 | 重庆泰濠制药有限公司 | 卡巴他赛的结晶形式及其制备方法 |
| EP2880021A4 (en) * | 2012-07-31 | 2015-06-17 | Yung Shin Pharm Ind Co Ltd | AMORPHIC CABACITAXEL |
| CN102898406B (zh) | 2012-11-02 | 2014-12-03 | 上海金和生物技术有限公司 | 一种卡巴他赛晶体及其制备方法 |
| CN103058960B (zh) | 2012-12-12 | 2014-12-10 | 江苏奥赛康药业股份有限公司 | 卡巴他赛多晶型形式及其制备方法 |
-
2012
- 2012-07-25 CN CN201210259595.3A patent/CN102746258B/zh active Active
-
2013
- 2013-07-18 WO PCT/CN2013/079575 patent/WO2014015760A1/zh active Application Filing
- 2013-07-18 AU AU2013295924A patent/AU2013295924B2/en active Active
- 2013-07-18 JP JP2015514346A patent/JP6329135B2/ja active Active
- 2013-07-18 EP EP16162975.3A patent/EP3067348A1/en not_active Withdrawn
- 2013-07-18 CA CA2870569A patent/CA2870569A1/en not_active Abandoned
- 2013-07-18 IN IN1962MUN2014 patent/IN2014MN01962A/en unknown
- 2013-07-18 EP EP13822828.3A patent/EP2835369B1/en active Active
- 2013-07-18 CA CA2909500A patent/CA2909500C/en active Active
- 2013-07-18 US US14/399,513 patent/US9353076B2/en active Active
-
2016
- 2016-01-21 AU AU2016200343A patent/AU2016200343B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016200343A1 (en) | 2016-02-11 |
| CN102746258B (zh) | 2015-02-04 |
| AU2016200343B2 (en) | 2017-03-30 |
| EP3067348A1 (en) | 2016-09-14 |
| JP2015518012A (ja) | 2015-06-25 |
| CA2909500A1 (en) | 2014-01-30 |
| AU2013295924B2 (en) | 2016-02-18 |
| EP2835369A1 (en) | 2015-02-11 |
| US20150141674A1 (en) | 2015-05-21 |
| WO2014015760A1 (zh) | 2014-01-30 |
| EP2835369A4 (en) | 2015-12-02 |
| JP6329135B2 (ja) | 2018-05-23 |
| CN102746258A (zh) | 2012-10-24 |
| AU2013295924A1 (en) | 2014-10-23 |
| EP2835369B1 (en) | 2019-04-03 |
| CA2870569A1 (en) | 2014-01-30 |
| CA2909500C (en) | 2018-01-09 |
| US9353076B2 (en) | 2016-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01962A (ru) | ||
| IN2014MN01755A (ru) | ||
| PH12016500164A1 (en) | Therapeutically active compounds and their methods of use | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| NZ706739A (en) | Substituted benzene compounds | |
| EA201592068A1 (ru) | Ингибиторы энхансера zeste гомолога 2 | |
| NZ715747A (en) | Syk inhibitors | |
| NZ739760A (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| MY178621A (en) | Deuterated cftr potentiators | |
| CR20200479A (es) | COMPUESTOS TERAPÉUTICAMENTE ACTIVOS Y SUS MÉTODOS DE USO (Divisional 2016-0069) | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| MX349159B (es) | Derivados deuterados de ivacaftor. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| MX347616B (es) | Inhibidores de csf-1r para el tratamiento de tumores de cerebro. | |
| IN2015DN01151A (ru) | ||
| NZ700612A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
| MX2014003376A (es) | Derivados de acido benzoico como inhibidores eif4e. | |
| TN2015000574A1 (en) | Compounds and compositions as inhibitors of mek | |
| NZ736970A (en) | Process methods for phosphatidylinositol 3-kinase inhibitors | |
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
| MX2015008187A (es) | Inhibidores de alk deuterados. | |
| IN2013DN02555A (ru) | ||
| WO2012112232A8 (en) | METHODS AND COMPOSITIONS FOR TREATING β-THALASSEMIA AND SICKLE CELL DISEASE | |
| IN2014DN00123A (ru) | ||
| IN2015DN01329A (ru) |